Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Notes Payables (2020 - 2022)

Historic Notes Payables for Seres Therapeutics (MCRB) over the last 4 years, with Q4 2022 value amounting to $456000.0.

  • Seres Therapeutics' Notes Payables changed N/A to $456000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $456000.0, marking a year-over-year change of. This contributed to the annual value of $456000.0 for FY2022, which is N/A changed from last year.
  • As of Q4 2022, Seres Therapeutics' Notes Payables stood at $456000.0.
  • Seres Therapeutics' 5-year Notes Payables high stood at $9.3 million for Q3 2021, and its period low was $454000.0 during Q4 2020.
  • For the 3-year period, Seres Therapeutics' Notes Payables averaged around $4.0 million, with its median value being $3.3 million (2021).